Bold Therapeutics’ experienced management team, compelling product candidate and solid development plan is expected to lead to numerous clinical and preclinical value drivers in the short-, intermediate- and long-term.
Bold Therapeutics is currently soliciting institutional investors for a pre-IPO Series B round.
Interested investors are encouraged to connect with us to learn more.
Bold Therapeutics has extensive collaborations with leading academic centers to further advance the understanding of BOLD-100. Bold Therapeutics is always open to discussing new collaborations.
While Bold Therapeutics has generated compelling preclinical data across a wide variety of difficult-to-treat indications, Bold Therapeutics’ core development focus is on BOLD-100 in combination with FOLFOX for the treatment of gastric and pancreatic cancers. Bold Therapeutics has ample cGMP material available to support potential partnerships and is specifically interested in development collaborations in combination with other anti-cancer agents across a wide range of solid and liquid tumor combinations and as an antiviral in infectious disease.
Option Agreement with Hana Pharm (South Korea)
In May 2020, Bold Therapeutics signed a milestone-based option agreement with Hana Pharm. The agreement allows for the development and commercialization of BOLD-100 in South Korea in oncology indications. Hana Pharm will collaborate on Bold Therapeutics’ Phase 1b / 2a trial in gastric, pancreatic, colorectal and bile duct cancers – and explore the potential development of BOLD-100 in triple-negative breast cancer (TNBC).